Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2025-12-24 @ 11:30 PM
NCT ID:
NCT02194556
Eligibility Criteria:
Inclusion Criteria:
* Stage IV or IIIB advanced non-small cell lung cancer patients
* Positive EGFR Mutation
* Non-progressive disease after first-line gemcitabine/cisplatin therapy
* Measurable lesion according to RECIST 1.1 with at least one measurable lesion
Exclusion Criteria:
* Previous anti-EGFR (epidermal growth factor receptor) monoclonal antibody or small molecular agent such as gefitinib, erlotinib and so on
* Patients with wild-type EGFR
* Evidence of interstitial lung diseases
* Severe hypersensitivity to icotinib or any of the excipients of this product.
* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT02194556
Study Brief:
Protocol Section:
NCT02194556